253 related articles for article (PubMed ID: 26481041)
1. Growth inhibitory effect of an injectable hyaluronic acid-tyramine hydrogels incorporating human natural interferon-α and sorafenib on renal cell carcinoma cells.
Ueda K; Akiba J; Ogasawara S; Todoroki K; Nakayama M; Sumi A; Kusano H; Sanada S; Suekane S; Xu K; Bae KH; Kurisawa M; Igawa T; Yano H
Acta Biomater; 2016 Jan; 29():103-111. PubMed ID: 26481041
[TBL] [Abstract][Full Text] [Related]
2. Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-α2a for liver cancer therapy.
Xu K; Lee F; Gao SJ; Chung JE; Yano H; Kurisawa M
J Control Release; 2013 Mar; 166(3):203-10. PubMed ID: 23328125
[TBL] [Abstract][Full Text] [Related]
3. Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.
Benitez A; Yates TJ; Shamaldevi N; Bowen T; Lokeshwar VB
J Urol; 2013 Jul; 190(1):285-90. PubMed ID: 23228386
[TBL] [Abstract][Full Text] [Related]
4. Enzyme-mediated hyaluronic acid-tyramine hydrogels for the propagation of human embryonic stem cells in 3D.
Xu K; Narayanan K; Lee F; Bae KH; Gao S; Kurisawa M
Acta Biomater; 2015 Sep; 24():159-71. PubMed ID: 26112373
[TBL] [Abstract][Full Text] [Related]
5. Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells.
Yu X; Liu F; Zeng L; He F; Zhang R; Yan S; Zeng Z; Shu Y; Zhao C; Wu X; Lei J; Zhang W; Yang C; Wu K; Wu Y; An L; Huang S; Ji X; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Dai Z; Wang X; Liu B; Haydon RC; Luu HH; Gan H; He TC; Chen L
Cell Physiol Biochem; 2018; 47(3):957-971. PubMed ID: 29843133
[TBL] [Abstract][Full Text] [Related]
6. Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma.
Furuya N; Kamai T; Shirataki H; Yanai Y; Fukuda T; Mizuno T; Nakamura F; Kambara T; Nakanishi K; Abe H; Yoshida K
Cancer Immunol Immunother; 2011 Jun; 60(6):793-808. PubMed ID: 21350947
[TBL] [Abstract][Full Text] [Related]
7. Hyaluronidase-incorporated hyaluronic acid-tyramine hydrogels for the sustained release of trastuzumab.
Xu K; Lee F; Gao S; Tan MH; Kurisawa M
J Control Release; 2015 Oct; 216():47-55. PubMed ID: 26260452
[TBL] [Abstract][Full Text] [Related]
8. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
Sim MY; Huynh H; Go ML; Yuen JSP
PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 induces drug resistance in renal cell carcinoma.
Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
Tochizawa S; Masumori N; Yanai Y; Ohmoto Y; Yabuuchi Y; Tsukamoto T
Biomed Res; 2008 Dec; 29(6):271-8. PubMed ID: 19129670
[TBL] [Abstract][Full Text] [Related]
12. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S;
BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347
[TBL] [Abstract][Full Text] [Related]
14. An injectable hyaluronic acid-tyramine hydrogel system for protein delivery.
Lee F; Chung JE; Kurisawa M
J Control Release; 2009 Mar; 134(3):186-93. PubMed ID: 19121348
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor effect of local injectable hydrogel-loaded endostatin alone and in combination with radiotherapy for lung cancer.
Wang N; Gao Q; Tang J; Jiang Y; Yang L; Shi X; Chen Y; Zhang Y; Fu S; Lin S
Drug Deliv; 2021 Dec; 28(1):183-194. PubMed ID: 33427520
[TBL] [Abstract][Full Text] [Related]
16. Enzymatic conjugation of a bioactive peptide into an injectable hyaluronic acid-tyramine hydrogel system to promote the formation of functional vasculature.
Wang LS; Lee F; Lim J; Du C; Wan AC; Lee SS; Kurisawa M
Acta Biomater; 2014 Jun; 10(6):2539-50. PubMed ID: 24561710
[TBL] [Abstract][Full Text] [Related]
17. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
Wang X; Zhang L; Goldberg SN; Bhasin M; Brown V; Alsop DC; Signoretti S; Mier JW; Atkins MB; Bhatt RS
J Transl Med; 2011 Dec; 9():220. PubMed ID: 22188900
[TBL] [Abstract][Full Text] [Related]
18. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
Rosa R; Damiano V; Nappi L; Formisano L; Massari F; Scarpa A; Martignoni G; Bianco R; Tortora G
Br J Cancer; 2013 Aug; 109(3):686-93. PubMed ID: 23839492
[TBL] [Abstract][Full Text] [Related]
19. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
Roulin D; Waselle L; Dormond-Meuwly A; Dufour M; Demartines N; Dormond O
Mol Cancer; 2011 Jul; 10():90. PubMed ID: 21791089
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
